This content is from: Innovation

GSK Eyes $2B Acquisitions In India

GlaxoSmithKline is looking to make $2 billion worth of acquisitions to attain top rank in India, one of the world’s fastest-growing drug markets.

GlaxoSmithKline (GSK) is looking to make $2 billion worth of acquisitions to attain top rank in India, one of the world’s fastest-growing drug markets, The Wall Street Journal reports, citing The Times. GSK was seeking “bolt-on acquisitions” in Asia’s third-biggest economy to strengthen its emerging markets business, said CEO Andrew Witty.

Witty said he expected the company to spend between $500 million and $2 billion. The company was unlikely to pursue mergers and acquisitions on a larger scale and would not overpay for companies, he added.

Click here for the story from The Wall Street Journal.

Related Content